Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06592599
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-09
Brief Title:
Gemcitabine Docetaxel Toripalimab Induction in Epstein-Barr Virus EBV Associated Nasopharyngeal CarcinomaNPC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Safety Feasibility and Efficacy Study of Gemcitabine Plus Docetaxel Plus Toripalimab GDT Induction as Part of a Curative Sequential Chemoradiation for Patients With Locoregional EBV Associated Nasopharyngeal Carcinoma NPC
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None